Selective delivery of curcumin to breast cancer cells by self-targeting apoferritin nanocages with pH-responsive and low toxicity.


Journal

Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471

Informations de publication

Date de publication:
Dec 2022
Historique:
entrez: 1 4 2022
pubmed: 2 4 2022
medline: 6 4 2022
Statut: ppublish

Résumé

Breast cancer is prevalent and diverse with significantly high incidence and mortality rates. Curcumin (Cur), a polyphenol component of turmeric, has been widely recognized as having strong anti-breast cancer activity. However, its anti-cancer efficiency is largely impaired by some of its concomitant negative properties, including its poor solubility, low cellular uptake, and severe reported side effects. Hence, the necessity arises to develop a novel low-toxic and high-efficiency targeting drug delivery system (DDS). In this study, we developed a pH-sensitive tumor self-targeting DDS (Cur@HFn) based on self-assembled HFn loaded with Cur, in which Cur was encapsulated into HFn cavity by using a disassembly/reassembly strategy, and the Cur@HFn was characterized by ultraviolet-visible (UV-vis), dynamic light scattering (DLS), and transmission electron microscope (TEM). A variety of breast cancer cell models were built to evaluate cytotoxicity, apoptosis, targeting properties, and uptake mechanism of the Cur@HFn. The pharmacodynamics was also evaluated in tumor (4T1) bearing mice after intravenous injection.

Identifiants

pubmed: 35363115
doi: 10.1080/10717544.2022.2056662
pmc: PMC8979518
doi:

Substances chimiques

Drug Carriers 0
Apoferritins 9013-31-4
Curcumin IT942ZTH98

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

986-996

Références

Biomacromolecules. 2011 May 9;12(5):1629-40
pubmed: 21446722
J Control Release. 2018 Feb 10;271:31-44
pubmed: 29274436
Mol Pharm. 2017 Sep 5;14(9):3087-3097
pubmed: 28728419
J Biomater Appl. 2021 Feb;35(7):743-753
pubmed: 32807016
Colloids Surf B Biointerfaces. 2020 Jul;191:110982
pubmed: 32220813
Adv Healthc Mater. 2021 Feb;10(3):e2001196
pubmed: 33200571
Biomaterials. 2020 Aug;250:120059
pubmed: 32339858
Biomater Sci. 2021 May 18;9(10):3750-3761
pubmed: 33870964
Nanomedicine (Lond). 2020 Dec;15(29):2851-2869
pubmed: 33275041
Adv Sci (Weinh). 2021 Sep;8(17):e2004566
pubmed: 34197052
J Control Release. 2019 Oct;311-312:288-300
pubmed: 31494184
J Control Release. 2020 Oct 10;326:628-647
pubmed: 32653502
J Drug Target. 2020 Dec;28(10):1096-1109
pubmed: 32552125
Nanomaterials (Basel). 2020 Aug 08;10(8):
pubmed: 32784356
Biomolecules. 2021 Aug 31;11(9):
pubmed: 34572508
J Food Biochem. 2021 Sep;45(9):e13888
pubmed: 34331475
Adv Healthc Mater. 2019 Dec;8(23):e1900911
pubmed: 31701665
Int J Pharm. 2015 Jan 30;478(2):788-95
pubmed: 25528297
Nanoscale. 2015 Apr 21;7(15):6527-33
pubmed: 25786779
J Control Release. 2019 Dec 28;316:359-380
pubmed: 31682912
Adv Healthc Mater. 2021 Jun;10(11):e2002139
pubmed: 33870637
Int J Biol Macromol. 2020 Nov 1;162:748-761
pubmed: 32585267
J Mater Chem B. 2020 Dec 28;8(48):11096-11106
pubmed: 33210699
Adv Healthc Mater. 2021 Oct;10(20):e2100938
pubmed: 34218522
Biomater Sci. 2019 Apr 23;7(5):2123-2133
pubmed: 30869663
Colloids Surf B Biointerfaces. 2021 Jul;203:111759
pubmed: 33892283
J Control Release. 2020 Jul 10;323:191-202
pubmed: 31838201
Mater Sci Eng C Mater Biol Appl. 2018 Oct 1;91:859-867
pubmed: 30033321
Biomacromolecules. 2017 Oct 9;18(10):3318-3330
pubmed: 28886247
Biomater Sci. 2020 Jan 1;8(1):462-472
pubmed: 31750450
ACS Appl Mater Interfaces. 2019 Jul 24;11(29):25654-25663
pubmed: 31246402
ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6096-6106
pubmed: 29368506
Nat Commun. 2020 Dec 8;11(1):6290
pubmed: 33293545
Int J Nanomedicine. 2021 Feb 04;16:789-802
pubmed: 33568906
Adv Healthc Mater. 2020 Oct;9(19):e2001128
pubmed: 32893507
Int J Nanomedicine. 2020 Apr 02;15:2337-2349
pubmed: 32308385
ACS Appl Mater Interfaces. 2019 Jan 9;11(1):288-299
pubmed: 30539634
Nanoscale. 2021 Jan 28;13(3):1875-1883
pubmed: 33439183
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14900-5
pubmed: 25267615

Auteurs

Peng Ji (P)

College of Pharmacy and Chemistry & Chemical Engineering, Jiangsu Provincial Key Laboratory of Chiral Pharmaceutical Chemicals Biologically Manufacturing, Taizhou University, Taizhou, PR China.

Xianglong Wang (X)

College of Pharmacy and Chemistry & Chemical Engineering, Jiangsu Provincial Key Laboratory of Chiral Pharmaceutical Chemicals Biologically Manufacturing, Taizhou University, Taizhou, PR China.

Jiabing Yin (J)

College of Pharmacy and Chemistry & Chemical Engineering, Jiangsu Provincial Key Laboratory of Chiral Pharmaceutical Chemicals Biologically Manufacturing, Taizhou University, Taizhou, PR China.

Yi Mou (Y)

College of Pharmacy and Chemistry & Chemical Engineering, Jiangsu Provincial Key Laboratory of Chiral Pharmaceutical Chemicals Biologically Manufacturing, Taizhou University, Taizhou, PR China.

Haiqin Huang (H)

School of Pharmacy, Nantong University, Nantong, PR China.

Zhenkun Ren (Z)

The Third Hospital Affiliated of Jinzhou Medical University, Jinzhou, PR China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH